We kill cancer. Selectively.

Selective PhotoTherapy.

Potent cancer drugs.
Activated only where needed.

 

Imagine activating cancer drugs only where needed.
We’re developing a therapy that targets tumors with unmatched precision, sparing healthy tissue.
For patients who now face disfiguring surgery — or have no treatment options at all.

WHAT DO WE DO ?

At Lumox, we develop Selective PhotoTherapy: a new generation of targeted cancer therapy that combines:

  1. Tumor-targeting nanobodies: Derived from llamas, nanobodies serve as targeting tools, guiding light-activatable drugs directly to cancer cells.

  2. Light-activatable drugs: That can be controlled: when and where they are activated, and how cytotoxic they are. 

  3. Local Activation: The therapy uses local drug activation by exposing the tumor site to harmless light.

Selective PhotoTherapy enables a simple but powerful principle:

We control when and where the drug is activated. 

WHO ARE WE ?

Lumox is proud to be an Utrecht University spin-off company, derived from the group of Associate Professor Sabrina Oliveira

Our innovative therapy has undergone extensive validation in preclinical models and is currently undergoing successful experimentation in the veterinary clinic. The results are promising, showcasing robust antitumor activity coupled with a notable absence of side effects.

· The Technology ·

Head and Neck Cancer

· How It Works ·

· Core Team ·

Sebas Pronk, PhD

Chief Executive Officer

Sebas leads Lumox’s strategy, fundraising, and IP to bring Selective PhotoTherapy from the lab to patients.

Combining scientific expertise with entrepreneurial experience, he is building the company behind the technology.

Irati Beltrán Hernández, PhD

Chief Scientific Officer

Irati has spent over a decade developing Selective PhotoTherapy and knows the technology better than anyone.

She leads the science, nonclinical development, and regulatory affairs, preparing the platform for first-in-human studies.

 

Cristianne Rijcken, PhD

Chief Development Officer

Cristianne is an experienced biotech entrepreneur with a strong track record in drug development and company building.

She leads product development and CMC strategy, translating scientific innovation into a clinical product.

· Contact Us ·

Via the form below

Lumox B.V.

Address:
Princetonlaan 6, 3584 CB Utrecht, the Netherlands

Chamber of Commerce (KvK) number:
99056186